In the breakpoint cluster region (BCR) gene, however, this is more variable, occurring most commonly after e13 or e14 in CML and e1 and e2 in Ph+ ALL and Ph+ AML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.